Interview with Jacques Servier, Founder, Servier France
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Address: 22, Rue Garnier 92200 Neuilly sur Seine,France
Tel: +33 (0)1 55 72 60 00
Our entire activity is based on three key principles:
• Our chief principle, naturally, is to satisfy the needs of the physicians who prescribe our products and of the patients who benefit from them.
• Just as importantly, we want our research to contribute to the progress of medicine. Research to us is at least as vital as being an industry.
• Our third principle is all the more crucial as it is too often overlooked: it is that every person working for us should find fulfillment through and in what they do.
Figures
• Leading French independent pharmaceutical company
• Second French pharmaceutical company worldwide
• SERVIER is established in 140 countries
• 85% of SERVIER’s sales are achieved internationally
• Consolidated turnover for the 2007/2008 financial year: €3.7 billion
• More than 25% of SERVIER’s turnover is invested in Research and Development
• Worldwide workforce of over 20 000, including nearly 3 000 in Research and Development
• SERVIER contributes 29% of the trade surplus of France’s pharmaceutical industry
Osteoporosis
Diabetes
Cardiovascular
Venous Diseases
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this…
Nicolas Dufourt leads ALK France as General Manager, drawing on nearly two decades of tenure with the Danish allergy immunotherapy specialist. Under his stewardship, the French affiliate, comprising approximately 400…
France is reshaping its approach to obesity at a moment when scientific understanding, clinical practice and public expectations are all shifting. Dr Rudy Caillet offers a clear view of how…
With France at the forefront of rare disease expertise yet increasingly challenged on patient access, Amicus Therapeutics finds itself at the heart of both progress and paradox. In this interview,…
France has long been held up as Europe’s reference point for rare disease care – the first EU country with a national plan, a pioneer of coordinated expert networks, and…
With over two decades of international experience in the pharmaceutical industry, Olivier Zambelli brings both strategic vision and a deeply human approach to his role as President and General Manager…
With over 35 years of experience across major pharmaceutical markets, Corinne Blachier-Poisson, General Manager of Amgen France, she discusses Amgen France’s ambitions and the company’s pivotal role in shaping France’s…
After two decades with AstraZeneca across Europe and the United States, Anne-Laure Dreno now leads the group’s French affiliate at a time of exceptional scientific and organisational momentum. In this…
Launched in 2022 under the France 2030 biocluster programme, the Paris-Saclay Cancer Cluster (PSCC) is rapidly positioning itself as a new epicentre for oncology innovation in Europe. Under the leadership…
Founded in 1973, IFIS stands at the intersection of education, industry, and public policy, shaping the capabilities that underpin France’s global health leadership. Evolving from its origins as a training…
France is undergoing a quiet industrial renaissance in biomanufacturing, driven by a growing alignment between science, innovation, and policy. At the centre of this movement stands Laurent Lafferrère, CEO of…
With France now a cornerstone of its global strategy, Regeneron is accelerating its European expansion under the leadership of Antoine Catton. In less than two years, the affiliate has built…
See our Cookie Privacy Policy Here
